Precision Immunotherapy Shows Promise for Sepsis Treatment Through Targeted Patient Selection
Key Insights
A multinational randomized clinical trial demonstrates that precision immunotherapy tailored to patients' immune profiles significantly improved organ dysfunction in sepsis (search) patients.
The ImmunoSep study enrolled 276 patients across six countries, stratifying them based on immune status into macrophage activation-like syndrome (search) or sepsis-induced immunoparalysis (search) groups.
Patients receiving targeted immunotherapy showed 35.1% improvement in organ dysfunction compared to 17.9% in placebo group, though 28-day mortality rates remained unchanged.
A multinational randomized clinical trial has demonstrated that precision immunotherapy tailored to patients' underlying immune dysregulation significantly improved organ dysfunction in sepsis (search), marking a potential breakthrough in treating this heterogeneous and deadly syndrome. The ImmunoSep trial, published in JAMA, represents the first robust large-scale evidence that biomarker-guided, targeted selection of sepsis patients for immunotherapy leads to clinically meaningful improvement in outcomes.
Addressing the Challenge of Immune Heterogeneity
Sepsis (search) affects 49 million people worldwide annually, with 11 million deaths, making it a critical global health challenge. The syndrome is increasingly recognized as heterogeneous, with patients exhibiting divergent immune responses ranging from hyperinflammation to immune suppression. This variability has contributed to repeated failures of "one-size-fits-all" immunotherapies in previous clinical trials.
"The immune system reacts incorrectly to an infection in sepsis (search), but this can happen in different ways," explains Mihai Netea, professor of Experimental Internal Medicine at Radboudumc and leader of the consortium. "The immune system can be overly active, or it can become paralyzed. This depends on the type of microorganism causing the infection, the location of the infection, and the patient's immune status and overall health."
Study Design and Patient Stratification
The double-blind, placebo-controlled ImmunoSep study enrolled 276 patients with sepsis (search) across 33 centers in six countries between 2021 and 2024. Eligible patients met Sepsis-3 criteria and had pneumonia (search) or bacteremia (search) as the source of infection. The consortium analyzed the functional state of immune responses to determine how host defense mechanisms were functioning in sepsis patients.
Participants were stratified based on immune status into two distinct groups: those with macrophage activation-like syndrome (search), defined by markedly elevated ferritin (search) levels, and those with sepsis-induced immunoparalysis (search), characterized by low ferritin and reduced HLA-DR (search) expression on monocytes. These groups represent approximately a quarter of all sepsis (search) cases.
Patients were randomly assigned to receive standard care plus precision immunotherapy or standard care plus placebo for up to 15 days. Those with macrophage activation-like syndrome (search) received intravenous anakinra, an interleukin-1 receptor (search) antagonist that suppresses immune system activity. Patients with sepsis-induced immunoparalysis (search) were treated with subcutaneous recombinant human interferon gamma to stimulate immunity.
Significant Clinical Improvements Observed
The primary endpoint was improvement in organ dysfunction, defined as a decrease of at least 1.4 points in the Sequential Organ Failure Assessment (SOFA) score by day 9. This endpoint was achieved in 35.1% of patients in the precision immunotherapy group, compared with 17.9% in the placebo group, representing a statistically significant absolute difference of 17.2%.
"This study provides the first robust large-scale evidence that biomarker-guided, targeted selection of sepsis (search) patients for immunotherapy leads to clinically meaningful improvement in outcomes," says Evangelos Giamarellos-Bourboulis, professor of Internal Medicine and Infectious Diseases at the National and Kapodistrian University of Athens and President of the Hellenic Institute for the Study of Sepsis.
In the anakinra group treating patients with overactive immunity, patients performed three times better than controls. Additionally, underlying infections resolved sooner within the first 15 days of treatment across both immunotherapy groups.
Safety Profile and Mortality Outcomes
However, 28-day mortality did not differ significantly between the precision immunotherapy and placebo groups, suggesting that improved early organ function may not immediately translate into a survival benefit. Safety analyses revealed a high overall rate of serious treatment-emergent adverse events, reflecting the severity of illness in the study population.
Specific safety concerns included anemia occurring more frequently in patients receiving anakinra, while hemorrhagic events were more common in those treated with interferon gamma. These findings highlight the need for careful monitoring and risk-benefit assessment in clinical practice.
Future Directions for Personalized Sepsis Treatment
The investigators conclude that precision immunotherapy guided by immune profiling can improve organ dysfunction in sepsis (search), suggesting that immune-based stratification may represent a critical step toward more effective, personalized treatments. The research team emphasizes the need for further studies to assess long-term outcomes and survival benefits.
"The groups with overactive or paralyzed immunity in this study represent about a quarter of all sepsis (search) cases. For them, we aim to perform large follow-up studies in the near future to further validate our findings," notes Netea. "In addition, we will now also look for tailored immunotherapy for the remaining sepsis patients."
The researchers expect their study to provide a significant boost to the field of immunotherapy for sepsis (search) patients, potentially transforming treatment approaches from broad-spectrum interventions to precision medicine strategies based on individual immune profiles.